High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: A Center for International Blood and Marrow Transplant Research study

Mayo Clinic Proceedings

Volumn 81, Issue 7, 2006, Pages 880-888

  Vesole, David H ^a   Pérez, Waleska S ^b   Akasheh, Marwan ^c   Boudreau, Christian ^d   Reece, Donna E ^e   Bredeson, Christopher N ^f,g  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c KING HUSSEIN MEDICAL CENTER   (Jordan)

^d UNIVERSITY OF WATERLOO   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f Manitoba Blood and Marrow Transplant Program   (Canada)

^g CANCERCARE MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; PALIFERMIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; DRUG MEGADOSE; EXPERIENCE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; OVERALL SURVIVAL; PATIENT SELECTION; PROGNOSIS; RECIPIENT; RESEARCH; SURGICAL PATIENT; SURVIVAL RATE;

EID: 33745610729     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/81.7.880     Document Type: Article

References (43)

1. Kyle RA, Gertz MA, Greipp PR, et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood. 1999;93:1062-1066.
2. Gertz MA, Lacy MQ, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev. 2004;18:17-37.
3. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202-1207.
4. Gono T, Matsuda M, Dohi N, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med. 2003;42:72-77.
5. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004 Apr 15;103:2936-2938. Epub 2003 Dec 18.
6. Goodman HJB, Lachmann HJ, Bradwell AR, Hawkins PN. Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis [abstract]. Blood. 2004;104(11, pt 1):216a. Abstract 755.
7. Dhodapkar MV, Hussein MA, Rasmussen E, et al, United States Intergroup Trial Southwest Oncology Group. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 2004 Dec 1;104:3520-3526. Epub 2004 Aug 12.
8. Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma. 2003;3:241-246.
9. Dispenzieri A, Lacy MQ, Geyer SM, et al. Low dose single agent thalidomide is tolerated in patients with primary systemic amyloidosis, but responses are limited [abstract]. Blood. 2004;104(11, pt 2):312b. Abstract 4920.
10. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91:3662-3670.
11. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101: 766-769.
12. Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant. 1999;24:853-855.
13. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28:637-642.
14. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19:3350-3356.
15. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med. 2002;113:549-555.
16. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93.
17. Mollee PN, Wechalekar AD, Pereira DL, et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant. 2004;33:271-277.
18. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276-4282.
19. Gertz MA, Blood E, Vesole DH, Abonour R, Lazarus HM, Greipp PR. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant. 2004;34:149-154.
20. Blum W, Khoury H, Lin HS, et al. Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study. Biol Blood Marrow Transplant. 2003;9:397-404.
21. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361:1787-1789.
22. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant. 2004;34:1025-1031.
23. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004 Sep 15;104:1881-1887. Epub 2004 Mar 25.
24. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79:319-328.
25. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Data. New York, NY: Springer-Verlag; 1997:334-336.
26. Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multicentre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489-1500.
27. Solomon A, Weiss DT, Wall JS. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm. 2003;18:853-860.
28. Casserly LF, Fadia A, Sanchorawala V, et al. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int. 2003;63:1051-1057.
29. Dember LM, Sanchorawala V, Seldin DC, et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med. 2001;134:746-753.
30. Snanoudj R, Mamzer-Bruneel MF, Hermine O, Grunfeld JP, Chauveau D. Recovery of acute renal failure and nephrotic syndrome following autologous stem cell transplantation for primary (AL) amyloidosis. Nephrol Dial Transplant. 2003;18:2175-2177.
31. Seldin DC, Anderson JJ, Sanchorawala V, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004 Sep 15;104:1888-1893. Epub 2004 May 20.
32. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004 May 15;103:3960-3963. Epub 2004 Jan 22.
33. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751-3757.
34. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
35. 2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma: IX International Workshop in Multiple Myeloma, Salamanca, Spain [abstract]. Hematol J. 2003;4(suppl 1): S207.
36. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590-2598.
37. Sanchorawala V, Wright DG, Quillen K, et al. Treatment of AL amyloidosis with tandem cycles of high dose melphalan and autologous stem cell transplantation [abstract]. Blood. 2003;102(11, pt 1):117a-118a. Abstract 400.
38. Quillen K, Wright DG, Seldin DC, et al. Feasibility of second autologous peripheral blood stem cell (PBSC) collection followed by a second cycle of high dose melphalan (HDM) in patients relapsing after an initial course of HDM for the treatment of AL amyloidosis [abstract]. Blood. 2004;104(11, pt 2):391b-392b. Abstract 5226.
39. Attal M, Harousseau JL, Facon T, et al, InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma (published correction appears in N Engl J Med. 2004;350:2628). N Engl J Med. 2003;349:2495-2502.
40. Kroger N, Perez-Simon JA, Myint H, et al. Relapse prior to autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogenic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2004;10;698-708.
41. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003 Nov 1;102:3447-3454. Epub 2003 Jul 10.
42. Kawai Y, Kinoshita K, Arai H, et al. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan. Eur J Haematol. 2004;72:448-450.
43. Schoenland SO, Baccarani M, Campbell A, et al. Allogeneic and syngeneic hematopoietic cell transplants in patients with AL-amyloidosis: a report from the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Blood. 2004;104(11, pt 2):367b. Abstract 5133.